Pharmacodynamic endpoints included the total glucose-lowering effect of IDeg , ie the area under the glucose infusion rate ( GIR ) curve at steady state ( AUC ( GIR , , SS ) ) , and the maximum GIR at steady state ( GIR ( max , IDeg , SS ) ) .